Canadian Intellectual Property Office Issues Use Patent for Anipryl(R) - Draxis Strengthens Anipryl(R) Patent Rights.MISSISSAUGA, ONTARIO--(BUSINESS WIRE)--Feb. 14, 1997--DRAXIS Health Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on DRAXF, TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). DAX) DRAXIS Health Inc. today announced that it has received notification that the Canadian Intellectual Property Office The Canadian Intellectual Property Office (CIPO) is the patent, trademark, and copyright administration body of Canada. See also
Dr. Martin Barkin noted "We have ensured that the Anipryl(R) patent protection in both Canada and the United States The United States and Canada share a unique legal relationship. U.S. law looks northward with a mixture of optimism and cooperation, viewing Canada as an integral part of U.S. economic and environmental policy. is broad and clear. In addition, DRAXIS knows of no other product which is bioequivalent bi·o·e·quiv·a·lent n. A value indicating the rate at which a substance enters the bloodstream and becomes available to the body. to Anipryl(R) or which has been approved by the Health Protection Branch for the treatment of Canine Cushings Disease or Cognitive Dysfunction". Yesterday, Draxis announced that it had received Health Protection Branch approval for the use of Anipryl(R) in canine Cognitive Dysfunction which considerably broadens the Canadian market potential for Anipryl(R). DRAXIS Health Inc. is an emerging Toronto-based pharmaceutical company with three operating business units. The Canadian Pharmaceutical Marketing unit markets and sells prescription pharmaceuticals in Canada, the Dermatology unit researches, markets and sells prescription and over the counter dermatologicals including podiatrics in Canada and the US. The Veterinary unit, through its wholly owned US subsidiary, Deprenyl Animal Health, Inc., researches, develops, markets and sells prescription pharmaceuticals for companion animals. Products currently under development include Modafinil for narcolepsy narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and recurring unwanted episodes of sleep ("sleep attacks"). People with narcolepsy may abruptly fall asleep at almost any time, including while talking, eating, or even walking. and proprietary liposomed topical products for both the prescription and over-the-counter markets. DRAXIS also has a 30 percent interest in STEF STEF Sesqui Teaching Equipment Fund International Corp. (CDN (Content Delivery Network) A system of distributed content on a large intranet or the public Internet in which copies of content are replicated and cached throughout the network. :STEF; NASDAQ Bulletin Board:SEFFF), a network marketing company specializing in science-based, consumer health products. Except for historical information, this news release contains certain forward looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, clinical trial results, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time-to-time in the Company's filings with the U.S. Securities and Exchange Commission and Canadian securities authorities. To receive additional information on DRAXIS Health Inc. via fax at no charge, dial 1-800-PRO-INFO and enter code DRAXF. CONTACT: DRAXIS Health Inc. Kendall McAlister, 905/677-5500 ext 248 or Small Capital Equity Investor Relations Investor relations The process by which the corporation communicates with its investors. , Ltd. Robert Grahovar, 416/368-7459 or The Financial Relations Board, Inc. Paula Schwartz, 212/661-8030 or The Financial Relations Board, Inc. Brian Gill, 212/661-8030 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion